Expert Review of Neurotherapeutics最新文献

How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder? 白细胞介素-6受体拮抗剂如何影响视神经脊髓炎谱系障碍的未来？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-06 DOI: 10.1080/14737175.2026.2669297

Murat Kürtüncü

引用次数: 0

Treating the root cause of tension-type headache: when analgesics address the symptom but not the disorder. 治疗紧张性头痛的根本原因：当镇痛剂解决症状而不是疾病。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-05 DOI: 10.1080/14737175.2026.2668457

Modar Khalil, Fayyaz Ahmed

引用次数: 0

Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome. 16p11.2缺失综合征首个精准医学随机安慰剂对照试验的基本原理和研究设计。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-04 DOI: 10.1080/14737175.2026.2655767

Hannah M Rea, Julia T Mattson, Vardan Arutiunian, Alyssa Verdes, Suvekcha Bhattachan, Megha Santhosh, Abigail Garcia, Anika Ajwani, Meaghan Bowen, Susan Faja, Ellen Hanson, Katherine Pawlowski, Robin P Kochel, Lisa Prock, Jeremy Veenstra-VanderWeele, Karen Walton-Bowen, Adam Vogel, Angela Morgan, Sara Jane Webb, Paul P Wang

{"title":"Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome.","authors":"Hannah M Rea, Julia T Mattson, Vardan Arutiunian, Alyssa Verdes, Suvekcha Bhattachan, Megha Santhosh, Abigail Garcia, Anika Ajwani, Meaghan Bowen, Susan Faja, Ellen Hanson, Katherine Pawlowski, Robin P Kochel, Lisa Prock, Jeremy Veenstra-VanderWeele, Karen Walton-Bowen, Adam Vogel, Angela Morgan, Sara Jane Webb, Paul P Wang","doi":"10.1080/14737175.2026.2655767","DOIUrl":"https://doi.org/10.1080/14737175.2026.2655767","url":null,"abstract":"Chromosome 16p11.2 deletion syndrome is a genetic syndrome that includes difficulties in speech, language, and motor coordination. Arbaclofen, a selective GABA-B receptor agonist, has improved motor functioning and memory in mouse models. Prior clinical trials of arbaclofen in fragile X syndrome and autism spectrum disorder suggested benefit for social communication. L16hthouse (NCT04271332) is a multi-site, double-blind, randomized, placebo-controlled phase 2 trial to evaluate safety, efficacy, and tolerability of arbaclofen compared in 60 youths with 16p11.2 deletion syndrome (5 to 17:11 years) randomized on a 1:1 ratio. Primary outcomes included speech articulation, measured by the Goldman Fristoe Test of Articulation 3 (GFTA-3). Secondary outcomes included objective dysarthria indices, memory, motor control, and cognitive function, assessed with both standardized clinical measures and novel, computer-based assessments with automated scoring. Exploratory outcomes included attention, autism traits, and electrophysiological responses. L16hthouse is the first randomized trial in 16p11.2 deletion syndrome and uses an array of novel outcome measures to assess potential benefit in this population. In addition to providing potential insights about the safety, efficacy, and tolerability of arbaclofen, L16hthouse will provide an initial assessment of how these developmental outcome measures perform in a clinical trial across a broad age range.Clinical trial registration number: NCT04271332; 2020-02-13.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel treatment strategies for the management of refractory bipolar disorder. 管理难治性双相情感障碍的新治疗策略。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-31 DOI: 10.1080/14737175.2026.2653176

Ezequiel Lafont, Arielle M Morris, Krishna Patel, Sydney Demchak, Candace Chan, Timothy R Rice

{"title":"Novel treatment strategies for the management of refractory bipolar disorder.","authors":"Ezequiel Lafont, Arielle M Morris, Krishna Patel, Sydney Demchak, Candace Chan, Timothy R Rice","doi":"10.1080/14737175.2026.2653176","DOIUrl":"10.1080/14737175.2026.2653176","url":null,"abstract":"Introduction: Bipolar disorder is often treatable with conventional psychopharmacology. Despite the availability of numerous established treatments for bipolar disorder, cases of treatment resistance persist. The identification of optimal therapies proves challenging, as the term treatment resistance lacks a clear, standardized definition. Ambiguity in defining frequency, duration, and number of medication failures across the different subtypes of refractory bipolar disorder contributes to an inconsistent framework which negatively impacts both clinical decision making and clinical outcomes.Areas covered: This review article surveys updated novel treatments for the subtypes of refractory bipolar disorder in adult and pediatric populations. Treatment-resistant acute mania, rapid cycling, and bipolar depression in adult populations are reviewed, and studies in pediatric treatment-resistant bipolar disorder are overviewed. A literature search was conducted using MEDLINE and focused on studies published between 2015 and 2025 to highlight the latest research findings in this area of interest.Expert opinion: Future directions offer optimism through precision medicine, but a comprehensive conclusive survey of treatment-resistant bipolar disorder remains premature in its current state of research. Current challenges underscore the importance of creating a clearly defined classification system to improve diagnostic clarity and the consistency of research and clinical outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"461-476"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do people with bipolar disorder have a greater risk of dementia in later life? 双相情感障碍患者在以后的生活中患痴呆的风险更大吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-31 DOI: 10.1080/14737175.2026.2652297

Breno Satler Diniz

引用次数: 0

Centanafadine for the treatment of attention-deficit/hyperactivity disorder in adults: a plain language summary of publication. 辛他那定治疗成人注意力缺陷/多动障碍：发表摘要

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-04-01 DOI: 10.1080/14737175.2026.2642839

Caroline L Ward, Jessica Madera-McDonough, Mary Hobart, Denise Chang, Na Jin, Taisa Skubiak, Michael Liebowitz

引用次数: 0

Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance. 抗癫痫药物的药物基因组学：反应和耐受性遗传预测因子的系统综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-30 DOI: 10.1080/14737175.2026.2647028

Ainara Barguilla, Pau Riera, Victoria Ros-Castelló, Elena Muino, Alba Sierra-Marcos

{"title":"Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance.","authors":"Ainara Barguilla, Pau Riera, Victoria Ros-Castelló, Elena Muino, Alba Sierra-Marcos","doi":"10.1080/14737175.2026.2647028","DOIUrl":"10.1080/14737175.2026.2647028","url":null,"abstract":"Background: Effectiveness and tolerability of anti-seizure medications (ASM) vary widely among individuals with epilepsy. Genetic polymorphisms may influence pharmacokinetic and pharmacodynamic responses, yet available evidence is heterogeneous and inconsistently translated into clinical practice.Methods: A systematic search of eight databases (2000-2024) identified observational studies assessing associations between genetic variants and ASM response or adverse drug reactions. The review protocol was registered in PROSPERO (CRD420251237140). Two reviewers independently performed screening, data extraction and quality assessment using the Newcastle-Ottawa Scale. Owing to methodological heterogeneity, a narrative synthesis was conducted.Results: A total of 168 studies were eligible. The strongest and most consistent associations involved HLA-B*15:02 and HLA-A*31:01 as predictors of severe cutaneous adverse reactions to carbamazepine, oxcarbazepine and phenytoin. CYP2C9 variants showed reproducible links to phenytoin toxicity. Associations involving ABCB1, SCN1A, SCN2A, GABRA1 and UGT2B7 for treatment response were reported, but findings varied across ASM classes and populations. Substantial ethnic variability was observed, particularly in Asian cohorts.Conclusions: Only a limited number of genetic polymorphisms currently demonstrate sufficient consistency for clinical translation, mainly HLA alleles predicting severe cutaneous reactions and CYP2C9 variants associated with phenytoin toxicity. Larger multiethnic studies with standardized outcome definitions are needed to clarify the therapeutic role of additional markers and support broader pharmacogenomic implementation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"485-495"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary and evolving perspectives on surgical therapies for essential tremor: deep brain stimulation and focused ultrasound. 原发性震颤手术治疗的当代和发展观点：深部脑刺激和聚焦超声。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-11 DOI: 10.1080/14737175.2026.2642844

Subeikshanan Venkatesan, Zachary Sorrentino, David Mampre, Vyshak Chandra, Justin Hilliard

{"title":"Contemporary and evolving perspectives on surgical therapies for essential tremor: deep brain stimulation and focused ultrasound.","authors":"Subeikshanan Venkatesan, Zachary Sorrentino, David Mampre, Vyshak Chandra, Justin Hilliard","doi":"10.1080/14737175.2026.2642844","DOIUrl":"10.1080/14737175.2026.2642844","url":null,"abstract":"Introduction: Deep brain stimulation (DBS) and focused ultrasound (FUS) are established interventions for medically refractory essential tremor (ET), traditionally targeting the ventral intermediate (Vim) nucleus of the thalamus. Emerging targets such as the dentato-rubro-thalamic tract (DRTT), cerebello-thalamic tract (CTT), and posterior subthalamic (PSA) area offer potential therapeutic advantages.Areas covered: DBS, with decades of use, offers adjustable, reversible, and often bilateral tremor control through implanted electrodes. FUS is a newer, incisionless MRI-guided technique delivering focused acoustic energy for lesioning, increasingly used in staged bilateral procedures. Evidence shows comparable tremor suppression, though DBS risks relate to hardware and surgery, while FUS more often causes sensory and gait disturbances. Early complication rates are similar. Targeting, while traditionally based on indirect stereotactic coordinates, is increasingly guided by atlas-based and tractography-based approaches, improving precision for both modalities.Expert opinion: DBS may be preferred for younger patients, those needing long-term modulation, or bilateral therapy. FUS is an appealing option for older individuals or those with surgical contraindications. Directional and closed-loop DBS as well as connectomics-based targeting are likely to define the next generation of ET interventions, offering more personalized, durable, and safer tremor control.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"443-460"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What place does daridorexant have in the treatment of Binge-Eating Disorder? daridorexant在暴食症的治疗中有什么作用？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-18 DOI: 10.1080/14737175.2026.2647034

Anna Pan, Luigi Piccirilli, Massimiliano Buoli

引用次数: 0

Preferences, tailoring, and self-tailoring in internet-delivered treatments: lessons learned. 互联网治疗中的偏好、定制和自定制：经验教训。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-30 DOI: 10.1080/14737175.2026.2652294

Gerhard Andersson, Per Carlbring

{"title":"Preferences, tailoring, and self-tailoring in internet-delivered treatments: lessons learned.","authors":"Gerhard Andersson, Per Carlbring","doi":"10.1080/14737175.2026.2652294","DOIUrl":"10.1080/14737175.2026.2652294","url":null,"abstract":"Introduction: Internet-delivered psychological treatments have been developed and tested in many trials and are also implemented.Areas covered: The authors focus on treatment preferences when clients are allowed to choose treatment orientation and how the treatment is set up. The literature was searched using Medline, Google Scholar and Scopus in November 2025, locating eight preference studies. They showed benefits in treatment satisfaction when preferences are included and possibly improved outcomes. The second focus was on tailored internet-delivered cognitive behavior therapy (ICBT). The authors review six recent controlled studies published from 2000 onwards on various subjects including COVID-19, domestic violence, chronic pain, climate distress, depression in older adults in Lithuania, and young adults with anxiety and depression in Brazil. These examples are in line with previous findings showing that tailored ICBT is effective, despite there being no clear benefits over diagnosis-specific or transdiagnostic ICBT. Finally, the authors reviewed published findings from two trials demonstrating that self-tailoring can work without clinician input.Expert opinion: There are robust findings showing that tailored internet interventions are effective, with further indication that preferences and self-tailoring may work too. Future research will likely incorporate artificial intelligence tools to a greater extent to improve treatment efficacy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"477-483"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0